BeOne Medicines AG

NasdaqGS:ONC 주식 리포트

시가총액: US$39.9b

BeOne Medicines 향후 성장

Future 기준 점검 4/6

BeOne Medicines (는) 각각 연간 27.5% 및 12.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 24.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 22.3% 로 예상됩니다.

핵심 정보

27.5%

이익 성장률

24.60%

EPS 성장률

Biotechs 이익 성장28.8%
매출 성장률12.4%
향후 자기자본이익률22.32%
애널리스트 커버리지

Good

마지막 업데이트09 Sep 2026

최근 향후 성장 업데이트

분석 기사 • May 08

Results: BeOne Medicines AG Beat Earnings Expectations And Analysts Now Have New Forecasts

As you might know, BeOne Medicines AG ( NASDAQ:ONC ) just kicked off its latest quarterly results with some very strong...

Recent updates

내러티브 업데이트 • Sep 03

ONC: Oncology And Hema Pipeline Execution Into 2026 Will Drive Re Rating

BeOne Medicines’ analyst fair value estimate has been revised higher to $507.75 from $495.11, reflecting updated models that factor in recent beat and raise Q2 results, higher projected revenue growth, a slightly higher discount rate, a modestly lower profit margin assumption, and a richer future P/E expectation in line with analysts' focus on its advancing oncology and hema pipelines. Analyst Commentary Recent Street research on BeOne Medicines points to a broadly constructive tone, with multiple bullish analysts lifting price targets after the latest beat and raise Q2 results and pipeline updates.
내러티브 업데이트 • Aug 20

ONC: Hematology Pipeline And Solid Tumor Catalysts Will Drive Future Upside

BeOne Medicines' analyst fair value estimate has shifted to $433.02 from $412.35, as analysts factor in higher price targets following recent beat and raise quarters, supported by progress across both solid tumor and hematology pipelines. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive tone, with most firms adjusting price targets higher after the latest beat and raise quarter and pipeline updates.
분석 기사 • Aug 12

Solid Earnings Reflect BeOne Medicines' (NASDAQ:ONC) Strength As A Business

When companies post strong earnings, the stock generally performs well, just like BeOne Medicines AG's ( NASDAQ:ONC...
내러티브 업데이트 • Aug 06

ONC: Hematology Execution And 2026 Readouts Will Support Re Rating

BeOne Medicines' updated analyst price target edges higher as analysts factor in a fair value estimate moving to about $495, a slightly higher discount rate, more moderate revenue growth, improved profit margin expectations, and a lower assumed future P/E multiple following recent research updates from major firms. Analyst Commentary Recent research updates paint a constructive picture for BeOne Medicines, with several bullish analysts highlighting a mix of product execution, pipeline progress, and sector positioning as key supports for the stock's current valuation framework.
Seeking Alpha • Jul 30

BeOne Medicines: Owning The Full B-Cell Treatment Sequence

Summary BeOne Medicines is transitioning from a BRUKINSA-driven story to an integrated hematology and oncology platform with multiple growth drivers. Q1 2026 results show 35.5% revenue growth, expanding margins, and rising profitability, supporting a premium valuation justified by strong operational leverage. BRUKINSA, BEQALZI, and tacabrutideg form a defensible three-asset hematology moat, while a solid-tumor pipeline and manufacturing expansion drive future diversification. Despite high concentration risk and a demanding valuation, ONC’s evolving product ecosystem and cash flow generation underpin a bullish outlook. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 13

ONC: Hematology Leadership And Solid Tumor Data Will Drive Future Upside

Analysts have nudged their fair value estimate for BeOne Medicines higher from $336.98 to $344.15, reflecting updated assumptions around revenue growth, profit margins, and Brukinsa and pipeline momentum cited in recent price target increases across the Street. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive stance, with several firms lifting price targets in conjunction with sector-wide optimism around biotech earnings and deal activity.
내러티브 업데이트 • Jun 24

ONC: Hematology Data And Solid Tumor Readouts Will Drive Future Upside

Analysts have nudged their average price targets higher for BeOne Medicines, pointing to recent FDA progress on sonrotoclax and encouraging ASCO solid tumor data as key reasons for modestly higher fair value estimates and slightly adjusted assumptions on growth, margins and future P/E. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive tone, with several bullish analysts adjusting their models after new clinical data and the FDA decision on sonrotoclax.
내러티브 업데이트 • Jun 06

ONC: Hematology Leadership And Solid Tumor Pipeline Will Drive Future Upside

Analysts have nudged the fair value estimate for BeOne Medicines to about $337 per share, citing higher price targets from several firms as they factor in the recent accelerated approval of sonrotoclax and updated views on the company’s solid tumor pipeline. Analyst Commentary Recent research on BeOne Medicines reflects a mixed set of views.
내러티브 업데이트 • May 23

ONC: Hematology Franchise And Upcoming Trial Readouts Will Support Future Upside

Analysts lifted the price target on BeOne Medicines by $3 to $411.51, as updated models reflect the recent FDA accelerated approval for sonrotoclax in relapse and refractory mantle cell lymphoma, along with ongoing combination trials and a higher assumed profit margin that more than offsets slightly lower projected revenue growth and a reduced future P/E multiple. Analyst Commentary Recent research on BeOne Medicines centers on how the first FDA accelerated approval for sonrotoclax and the outlook for Brukinsa affect valuation, growth expectations, and perceived execution risk.
분석 기사 • May 08

Results: BeOne Medicines AG Beat Earnings Expectations And Analysts Now Have New Forecasts

As you might know, BeOne Medicines AG ( NASDAQ:ONC ) just kicked off its latest quarterly results with some very strong...
내러티브 업데이트 • Apr 30

ONC: Hematology Leadership And 2026 Pipeline Readouts Will Re Rate Shares

BeOne Medicines' updated analyst price target reflects a modest adjustment, with fair value moving by about $1 per share as analysts balance slightly higher revenue and profit margin assumptions with a lower future P/E multiple following recent target changes and mixed rating updates across the Street. Analyst Commentary Recent research updates on BeOne Medicines show a mix of views, but there is a clear cluster of bullish analysts who see support for the current valuation and room for further upside based on execution around core products and the pipeline.
내러티브 업데이트 • Apr 16

ONC: Hematology Strength And Slower Pipeline Progress Will Shape Fairly Valued Shares

The updated analyst price target for BeOne Medicines shifts to $336 from $321, as analysts factor in slightly higher modeled revenue growth, profit margins, and future P/E assumptions, alongside mixed recent research that includes both trims and increases in published targets. Analyst Commentary Recent research around BeOne Medicines reflects a mix of enthusiasm for its core hematology asset and a more cautious reset on what investors should pay for that story.
내러티브 업데이트 • Apr 02

ONC: Hematology Pipeline Strength And Upcoming Data Readouts Will Drive Future Upside

BeOne Medicines' analyst price target has been nudged higher to reflect a fair value estimate of about $408, as analysts balance slightly softer long term growth and margin assumptions with ongoing confidence in Brukinsa and the broader hematology pipeline, including support from several recent target hikes and one downgrade to Hold. Analyst Commentary Bullish Takeaways Bullish analysts highlight Brukinsa as a core value driver, treating it as one of the stronger hematology assets and a key pillar supporting current fair value estimates in the low $400s.
내러티브 업데이트 • Mar 19

ONC: Hematology Franchise Strength And Pipeline Readouts Will Re Rate Shares

BeOne Medicines' updated analyst price target has moved lower, reflecting a reduced fair value estimate to $478.80 as analysts factor in more moderate revenue growth, slimmer profit margins, a slightly higher discount rate, and a higher future P/E multiple. This multiple is anchored by strong Brukinsa performance but a slower build for the next wave of assets.
내러티브 업데이트 • Mar 04

ONC: Brukinsa Reliance And Hematology Pipeline Will Shape Fairly Valued Shares

The analyst price target for BeOne Medicines has been nudged higher by about $13 to align with a fair value update to roughly $321. Analysts are factoring in Q4 results, ongoing Brukinsa performance, and a higher future P/E assumption, alongside slightly more conservative revenue growth and profit margin inputs.
내러티브 업데이트 • Feb 18

ONC: Hematology Pipeline Hype Will Pressure Shares If Execution Slips

Analysts have raised their price targets on BeOne Medicines by $9, citing a pipeline they view as underappreciated by the market and supporting that view with updated assumptions regarding growth, profitability, and valuation multiples. Analyst Commentary Recent research has centered on how fully the market is pricing BeOne Medicines' drug pipeline and long term earnings power into the current share price.
내러티브 업데이트 • Feb 04

ONC: Hematology And Solid Tumor Pipeline Progress Will Drive Future Upside

Analysts lifted their price target for BeOne Medicines to about $404, up roughly $3, citing increased conviction in the value of its hematology and solid tumor pipeline, which is reflected in a slightly higher assumed future P/E multiple. Analyst Commentary Recent research updates on BeOne Medicines cluster around a similar theme: bullish analysts are raising price targets and citing comfort with both the hematology and solid tumor franchises, while also highlighting execution risks that investors should keep in mind.
내러티브 업데이트 • Jan 21

ONC: Hematology Franchise And Oncology Pipeline Are Expected To Re Rate Shares

Analysts have lifted their price targets on BeOne Medicines into the low US$400s, and our fair value estimate has edged up to about US$508 as they highlight what they see as underappreciation of the pipeline, the potential for best in class hematology assets, and additional upside from oncology trial updates. Analyst Commentary Recent Street research on BeOne Medicines has tilted clearly positive, with a series of price target increases into the low US$400s range and at least one rating upgrade.
내러티브 업데이트 • Jan 07

ONC: Fair View Balances Blood Cancer Progress With Gastroesophageal Cancer Opportunity

The analyst price target for BeOne Medicines has moved higher to reflect a fair value estimate of $292.03, with analysts pointing to stronger modeled revenue growth and profit margins, supported by recent Street research around Brukinsa performance, Ziihera phase III progress in HER2-positive GEA with Tevimbra, and continued confidence in the CLL and solid tumor pipeline. Analyst Commentary Recent Street research on BeOne Medicines has generally pointed to constructive views on the company’s core franchises, with several price targets adjusted higher alongside updates on Brukinsa, sonrotoclax, and the broader CLL and solid tumor pipeline.
내러티브 업데이트 • Dec 14

ONC: Priority Review And Trial Progress Will Drive Future Upside Momentum

Analysts have nudged their blended price target for BeOne Medicines up by about $3 to roughly $402, citing stronger confidence in the chronic lymphocytic leukemia and solid tumor pipelines, recent Ziihera and Tevimbra data, and repeated quarterly beats that support steadily improving margins despite a slightly higher discount rate. Analyst Commentary Bullish analysts point to a broad set of recent price target hikes in the high $380s to low $420s range as evidence that the market is re-rating BeOne Medicines higher on both execution and pipeline visibility.
내러티브 업데이트 • Nov 29

ONC: Priority Review And Trial Updates Will Drive Momentum Amid Sector Risks

BeOne Medicines’ analyst price target has edged up from $395 to $399, as analysts point to key clinical updates and solid quarterly performance as catalysts for incremental upside. Analyst Commentary Recent research notes from Street analysts highlight both strengths and risks for BeOne Medicines as the company navigates pivotal clinical developments and posts strong financial results.
내러티브 업데이트 • Nov 15

ONC: Pipeline Data And Conference Updates Will Shape Outlook Amid Sector Risks

Analysts have increased their fair value estimate for BeOne Medicines to $395.37 from $382.29, citing strong quarterly results as well as an improved outlook for key therapies and pipeline advancements. Analyst Commentary Bullish analysts emphasized several positive trends in BeOne Medicines' recent performance and outlook, resulting in a series of raised price targets and continued positive ratings.
분석 기사 • Nov 14

We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve

Even though BeOne Medicines AG's ( NASDAQ:ONC ) recent earnings release was robust, the market didn't seem to notice...
내러티브 업데이트 • Nov 01

ONC: Pivotal Oncology Trial Data Will Drive Future Upside Momentum

BeOne Medicines' fair value price target has risen modestly by $1.20 to $382.29. Analysts cite increased confidence in peak sales for sonrotoclax and the company's broadly advancing oncology pipeline as key drivers for the upward adjustment.
내러티브 업데이트 • Oct 17

Oncology Trials And Global Expansion Will Unlock Future Markets

Analysts have raised their fair value price target for BeOne Medicines from $372.97 to $381.09. They cite accelerating revenue growth, an improved profit margin outlook, and positive pivotal trial catalysts as reasons for their more optimistic projections.
내러티브 업데이트 • Oct 03

Oncology Trials And Global Expansion Will Unlock Future Markets

Analysts have increased their fair value price target for BeOne Medicines by approximately $5 to $372.97. They cite robust Q2 sales growth, encouraging pipeline developments, and upward revisions to revenue forecasts as reasons for the adjustment.
내러티브 업데이트 • Sep 18

Oncology Trials And Global Expansion Will Unlock Future Markets

BeOne Medicines’ consensus price target was raised to $367.68, reflecting analyst optimism driven by robust sales growth, positive pipeline updates, profitability, and increased revenue guidance. Analyst Commentary Bullish analysts highlight BeOne Medicines’ broad oncology pipeline and upcoming pivotal data readouts—specifically BTK inhibitor data in mantle cell lymphoma and PD1 inhibitor/anti-HER2 combination results in gastroesophageal cancer—as key drivers for durable growth.
내러티브 업데이트 • Sep 03

Oncology Trials And Global Expansion Will Unlock Future Markets

The consensus analyst price target for BeOne Medicines was raised to $363.30, primarily driven by strong Brukinsa Q2 sales, improved forward revenue guidance, and ongoing pipeline progress. Analyst Commentary Bullish analysts cite robust Q2 sales growth, particularly from Brukinsa in the US and EU, as the main driver for upward price target revisions.
내러티브 업데이트 • Aug 08

Oncology Trials And Global Expansion Will Unlock Future Markets

With both revenue growth and net profit margin expectations remaining essentially unchanged, analysts have maintained BeOne Medicines’ fair value at a consensus price target of $357.18. What's in the News BeOne Medicines raised 2025 revenue guidance to $5.0–$5.3 billion, now expecting positive GAAP operating income.

이익 및 매출 성장 예측

NasdaqGS:ONC - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20288,7111,5801,7392,08828
12/31/20277,7191,1751,1981,53734
12/31/20266,7508498221,01132
6/30/20266,1296561,3091,484N/A
3/31/20265,7395131,0941,285N/A
12/31/20255,3432878611,128N/A
9/30/20254,97369464785N/A
6/30/20254,562-178165571N/A
3/31/20254,176-392-240212N/A
12/31/20243,810-645-670-141N/A
9/30/20243,306-822-1,195-603N/A
6/30/20243,097-524-1,356-704N/A
3/31/20242,763-784-1,566-902N/A
12/31/20232,459-882-1,754-1,157N/A
9/30/20232,143-976-1,652-1,058N/A
6/30/20231,811-1,732-2,283-1,738N/A
3/31/20231,557-1,917-2,298-1,824N/A
12/31/20221,416-2,004-1,966-1,497N/A
9/30/20221,250-2,149-2,144-1,686N/A
6/30/20221,069-2,030-2,016-1,620N/A
3/31/2022877-1,960-2,044-1,660N/A
12/31/20211,176-1,458-1,614-1,299N/A
9/30/20211,062-1,340-1,334-1,123N/A
6/30/2021947-1,327-1,193-974N/A
3/31/2021863-1,167-1,030-816N/A
12/31/2020309-1,625-1,510-1,283N/A
9/30/2020266-1,512-1,426-1,218N/A
6/30/2020225-1,394-1,301-1,137N/A
3/31/2020402-1,145N/A-920N/A
12/31/2019428-949N/A-750N/A
9/30/2019430-829N/A-677N/A
6/30/2019434-665N/A-544N/A
3/31/2019244-737N/A-615N/A
12/31/2018198-674N/A-548N/A
9/30/2018158-505N/A-260N/A
6/30/2018324-243N/A-121N/A
3/31/2018271-147N/A-56N/A
12/31/2017238-93N/A13N/A
9/30/2017220-31N/A-107N/A
6/30/2017N/A-184N/A-138N/A
3/31/20170-148N/A-105N/A
12/31/20161-119N/A-90N/A
9/30/20166-109N/A-80N/A
6/30/20167-87N/A-66N/A
3/31/20168-69N/A-56N/A
12/31/20159-57N/A-40N/A
9/30/20156-34N/A-34N/A

애널리스트 향후 성장 전망

수입 대 저축률: ONC 의 연간 예상 수익 증가율(27.5%)이 saving rate(3.7%)보다 높습니다.

수익 vs 시장: ONC 의 연간 수익(27.5%)이 US 시장(17.3%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: ONC 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: ONC 의 수익(연간 12.4%)이 US 시장(연간 13.5%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: ONC 의 수익(연간 12.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ONC의 자본 수익률은 3년 후 22.3%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/09/10 11:08
종가2026/09/10 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

BeOne Medicines AG는 70명의 분석가가 다루고 있습니다. 이 중 34명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Tianli WenAletheia Analyst Network Limited
Brian SkorneyBaird
Peter LawsonBarclays